Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?

Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
Best Practice for Newly Diagnosed Myeloma Patients Eligible for Transplant: How Can We Optimize Therapy?
CME, CPE
Muhamed Baljevic, MD
Release Date: March 31, 2021
Expiration Date: March 31, 2022

In this activity, Dr. Baljevic discusses patients with newly diagnosed multiple myeloma who are eligible for transplant and reviews recent data from trials evaluating novel multi-drug combinations in the frontline setting. He also identifies the management of treatment-emergent adverse events that are associated with different treatment approaches.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Takeda Oncology.
Begin, Earn CreditView Only, No CreditGet Certificate